Biomea Fusion announced positive results from its Phase II COVALENT-111 clinical trial for icovamenib in type 2 diabetes, showing a significant reduction in HbA1c levels after 12 weeks of treatment, with 225 patients enrolled and a placebo-adjusted mean reduction of 1.47%. The company plans to engage with the FDA to discuss these findings and advance icovamenib's development.